EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP).
Saved in:
| Title: | EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP). |
|---|---|
| Authors: | Ruiz-Patiño A; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia., Castro CD; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia., Ricaurte LM; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia., Cardona AF; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia. andres.cardona@clinicadelcountry.com.; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia. andres.cardona@clinicadelcountry.com.; Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad El Bosque, Bogotá, Colombia. andres.cardona@clinicadelcountry.com., Rojas L; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia.; Clinical Oncology Department, Clínica Colsanitas, Bogotá, Colombia., Zatarain-Barrón ZL; Thoracic Oncology Unit and Laboratory of Personalized Medicine, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico., Wills B; Internal Medicine Department, Johns Hopkins University, Baltimore, MD, USA., Reguart N; Medical Oncology Department, Hospital Clinic, Barcelona, Spain., Carranza H; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia.; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia., Vargas C; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia.; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia., Otero J; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia.; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia., Corrales L; Clinical Oncology Department, Hospital San Juan de Dios, San José, Costa Rica., Martín C; Thoracic Oncology Unit, Alexander Fleming Institute, Buenos Aires, Argentina., Archila P; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia., Rodriguez J; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia., Avila J; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia., Bravo M; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia., Pino LE; Medical Oncology Group, Fundación Santa Fe de Bogotá, Bogotá, Colombia., Rosell R; Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain., Arrieta O; Thoracic Oncology Unit and Laboratory of Personalized Medicine, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico. |
| Corporate Authors: | Latin-American Consortium for the Investigation of Lung Cancer (CLICaP) |
| Source: | Targeted oncology [Target Oncol] 2018 Oct; Vol. 13 (5), pp. 621-629. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1776-260X |
|---|---|
| DOI: | 10.1007/s11523-018-0594-x |
